Mountain Valley MD Files Patent And Begins Pre-clinical Trials To Enter USD $100 Billion Cancer Drug Market
Published
May 04 2021 at 4:39 PM GMT
Key
Points
Points
- VANCOUVER, BC, May 4, 2021 /PRNewswire/ - Mountain Valley MD (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) announced it has filed a novel cancer adjuvant patent related to breast cancer, metastatic melanoma, and lung carcinoma.
- Mountain Valley MD is a biotech and life sciences company.
Trending
Stats
- Published May 4, 2021 4:39 PM GMT